{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:01:19Z","timestamp":1790614879001,"version":"4.1.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,4,1]],"date-time":"2007-04-01T00:00:00Z","timestamp":1175385600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,2]],"date-time":"2015-12-02T00:00:00Z","timestamp":1449014400000},"content-version":"vor","delay-in-days":3167,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2007,4]]},"DOI":"10.1038\/sj.jid.5700693","type":"journal-article","created":{"date-parts":[[2007,3,16]],"date-time":"2007-03-16T06:24:14Z","timestamp":1174026254000},"page":"744-745","source":"Crossref","is-referenced-by-count":21,"title":["Soluble Fas Ligand: Is It a Critical Mediator of Toxic Epidermal Necrolysis and Stevens\u2013Johnson Syndrome?"],"prefix":"10.1016","volume":"127","author":[{"given":"Junko","family":"Murata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riichiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/sj.jid.5700693_bb0010","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0002-9440(10)64284-8","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand","volume":"162","author":"Abe","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1038\/sj.jid.5700693_bb0015","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens\u2013Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1038\/sj.jid.5700693_bb0020","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1046\/j.1523-1747.2002.01622.x","article-title":"Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis","volume":"118","author":"Nassif","year":"2002","journal-title":"J Invest Dermatol"},{"key":"10.1038\/sj.jid.5700693_bb0025","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/archderm.1994.01690050073012","article-title":"Macrophages and tumor necrosis factor alpha in toxic epidermal necrolysis","volume":"130","author":"Paquet","year":"1994","journal-title":"Arch Dermatol"},{"key":"10.1038\/sj.jid.5700693_bb0030","first-page":"3","article-title":"Clinical significance of serum soluble Fas ligand in patients with acute self-limited and fulminant hepatitis","volume":"101","author":"Shiota","year":"1998","journal-title":"Res Commun Mol Pathol Pharmacol"},{"key":"10.1038\/sj.jid.5700693_bb0035","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/sj.jid.5700648","article-title":"Soluble Fas ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas","volume":"127","author":"Stur","year":"2007","journal-title":"J Invest Dermatol"},{"key":"10.1038\/sj.jid.5700693_bb0040","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1084\/jem.20050707","article-title":"FASL -844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer","volume":"202","author":"Sun","year":"2005","journal-title":"J Exp Med"},{"key":"10.1038\/sj.jid.5700693_bb0045","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1038\/sj.jid.5700693_bb0050","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4049\/jimmunol.170.1.132","article-title":"A novel polymorphic CAAT\/enhancer-binding protein \u03b2 element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients","volume":"170","author":"Wu","year":"2003","journal-title":"J Immunol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X1533339X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X1533339X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T05:09:08Z","timestamp":1556255348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X1533339X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,4]]}},"alternative-id":["S0022202X1533339X"],"URL":"https:\/\/doi.org\/10.1038\/sj.jid.5700693","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2007,4]]}}}